Lanreotide - NDC Database

12 records found

Page:1

69097-870 Dec 24, 2021
Lanreotide Acetate 120 mg/.5ml Subcutaneous Injection by Cipla USA Inc.

69097-880 Dec 24, 2021
Lanreotide Acetate 60 mg/.2ml Subcutaneous Injection by Cipla USA Inc.

69097-890 Dec 24, 2021
Lanreotide Acetate 90 mg/.3ml Subcutaneous Injection by Cipla USA Inc.

69097-906 May 22, 2024
Lanreotide Acetate 120 mg/.5ml Subcutaneous Injection by Cipla USA Inc.

69097-907 May 22, 2024
Lanreotide Acetate 60 mg/.2ml Subcutaneous Injection by Cipla USA Inc.

69097-908 May 21, 2024
Lanreotide Acetate 90 mg/.3ml Subcutaneous Injection by Cipla USA Inc.

76282-709 Jun 01, 2022
Lanreotide Acetate 60 mg/.2ml Subcutaneous Injection by Exelan Pharmaceuticals, Inc.

76282-710 Jun 01, 2022
Lanreotide Acetate 90 mg/.3ml Subcutaneous Injection by Exelan Pharmaceuticals, Inc.

76282-711 Jun 01, 2022
Lanreotide Acetate 120 mg/.5ml Subcutaneous Injection by Exelan Pharmaceuticals, Inc.

76282-718 May 21, 2024
Lanreotide Acetate 60 mg/.2ml Subcutaneous Injection by Exelan Pharmaceuticals, Inc.

76282-719 May 21, 2024
Lanreotide Acetate 90 mg/.3ml Subcutaneous Injection by Exelan Pharmaceuticals, Inc.

76282-720 May 21, 2024
Lanreotide Acetate 120 mg/.5ml Subcutaneous Injection by Exelan Pharmaceuticals, Inc.

Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.